Death or life threatening side effects were not seen during follow-up. ABA is an acceptable treatment option in DMARD resistant biologic naive RA patients. Background: Janus kinase (JAK) inhibitors are being evaluated for treatment of active rheumatoid arthritis (RA). Understanding their onset of action on patient reported outcomes (PROs) and clinical endpoints in RA patients (pts) is limited. Objectives: To assess onset of benefit with ABT-494, a selective JAK1 inhibitor vs placebo (PBO) in RA pts with active disease ≥3 months in 2 randomized controlled trials (RCTs) evaluating safety and efficacy of ABT-494. M13-537 (NCT02066389) included pts who were inadequate responders to methotrexate (MTX-IR) and M13-550 (NCT01960855) to tumor necrosis factor inhibitors (TNF-IR). Methods: Data were analyzed separately for each RCT in pts who received 6mg or 12mg bid ABT-494 or PBO. Analyses included cumulative assessment of PROs such as patient global assessment of disease activity (PtGA), pain Visual Analogue Scale (VAS) and Health Assessment Questionnaire Disability Index (HAQ-DI) in terms of Routine Assessment of Patient Index Data 3 (RAPID3) scores, and clinical outcomes such as DAS28 (CRP) and CDAI. To assess onset and maintenance of effect, the number of pts whose improvements met or exceeded minimal important differences (MID) RAPID3: reduction ≥3.6; DAS28: reduction ≥1.2; CDAI: reduction ≥11.0 and were calculated at weeks 2 and 12. Additionally, Kaplan-Meier (KM) analysis estimated mean time to achievement of RAPID3, DAS28 and CDAI MID. Non-responder imputation accounted for missing data. Results: In M13-537 (N=150 pts) and M13-550 (N=166 pts) RCTs, significantly more pts in ABT-494 12mg groups reported improvements ≥MID in RAPID3 vs PBO at Wk 2: 68% vs 30% and 73% vs 38%, respectively (Table) . In M13-537, significantly more pts receiving ABT-494 6mg BID vs PBO (54% vs 30%) had improvements ≥MID in RAPID3. These responses were sustained throughout both trials in pts receiving 12mg ABT-494 (M13-537: 80%; M13-550: 71%). Significantly more pts achieved and maintained changes ≥MID in DAS28 in both RCTs and in CDAI in M13-550. Based on KM analyses, in M13-537, estimated mean time (±SE) to achievement of RAPID3 MID was shorter for both ABT-494 doses vs PBO (12mg: 3.9±0.5 weeks; 6mg: 3.9±0.4 weeks; PBO 6.0±0.6 weeks). Similarly, estimated mean time to these responses was shorter with both ABT-494 doses vs PBO (12mg: 3.6±0.4 weeks; 6mg: 4.9±0.6 weeks; PBO: 6.6±0.6 weeks) in M13-550, although it was underestimated due to censoring.
SAT0218 EFFECT OF TOCILIZUMAB IN DMARD-NAÏVE EARLY RHEUMATOID ARTHRITIS PATIENTS ON HEALTH-RELATED QUALITY OF LIFE: RESULTS OF THE U-ACT-EARLY TRIAL
Background: Tocilizumab (TCZ), a humanized interleukin-6 receptor inhibitor, has been shown effective in suppressing symptoms of rheumatoid arthritis (RA). In U-Act-Early, a significantly greater proportion of patients with early RA who initiated TCZ (84%) or TCZ plus MTX therapy (86%) achieved sustained remission (Disease Activity Score assessing 28 joints (DAS28) <2.6 with ≤4 swollen joints for ≥24 weeks), when compared to those initiating MTX (44%). [1] Objectives: To determine the effect of treat-to-target TCZ therapy, with or without MTX, on health-related quality of life (HRQoL) in disease modifying anti-rheumatic drugs (DMARD)-naïve patients with early RA. Methods: Patients (n=317) were randomized to initiate TZC, TCZ+MTX or MTX therapy and treated according to a step-up strategy. TCZ was given (8 mg/kg) every 4 weeks and MTX (oral) was started at 10 mg/week and increased with steps of 5 mg steps 4 weekly up to 30 mg/week (or maximum tolerable dose) until remission. If after 20 weeks remission was not achieved, hydroxychloroquine was added and discontinued 12 weeks thereafter if the target still was not achieved. Patients who originally initiated monotherapy then switched to TCZ+MTX therapy and those already on this combination therapy switched to a tumour necrosis factor inhibitor. To evaluate the effect of TCZ on HRQoL, we used the 36-item Short-Form (SF-36), which can be summarized into a physical (PCS) and mental (MCS) component score. HRQoL was measured at baseline and after 12, 24, 52, and 104 weeks. A linear mixed effect model with a random intercept was used to evaluate differences between treatment strategies over time with visit (time), strategy, baseline SF-36 score, baseline DAS28 level (i.e., DAS28 <5.1 or ≥5.1) and centre as fixed effects. The proportions of patients exceeding the minimum clinically important differences (MCID, ≥2.5-point increase from baseline) were tested for significance using the two-sided Pearson's chi-squared test. Results: We found significantly greater improvements over time in the SF-36 PCS in patients initiating treatment with TCZ (TCZ vs MTX; p=0.041, TCZ+MTX vs MTX; p=0.011, Fig. 1 ). For the SF-36 MCS, no significant differences over time were noted between the treatment arms (p≥0.11). A significantly higher proportion of patients initiating treatment with TCZ (76%; p=0.016, 89%; p=0.030) or TCZ+MTX (73%; p=0.049, 89%; p=0.027) achieved MCID in the SF-36 PCS at week 12 and week 52, when compared to those initiating treatment with MTX (59% and 73%, respectively). Although the proportions of patients achieving MCID in the SF-36 MCS were numerically higher in the TCZ arms, no significant differences were found (p≥0.06).
Conclusions:
Initiation of TCZ, with or without MTX, at start of therapy resulted in statistically significant and clinically relevant improvements in the HRQoL when compared to initiation of MTX alone and may be considered as a valuable treatment strategy in DMARD-naïve patients with early RA.
